Temelimab
{{Short description|Monoclonal antibody}}
{{Infobox drug
| drug_name = Temelimab
| type = mab
| mab_type = IgG4
| legal_status = Experimental
| CAS_number = 1393641-34-3
| UNII = T32CR1A69R
| DrugBank = DB15634
}}
Temelimab (also known as GNbAC1{{cite journal | vauthors = Irfan SA, Murtaza M, Ahmed A, Altaf H, Ali AA, Shabbir N, Baig MM | title = Promising role of temelimab in multiple sclerosis treatment | journal = Multiple Sclerosis and Related Disorders | volume = 61 | pages = 103743 | date = May 2022 | pmid = 35344907 | doi = 10.1016/j.msard.2022.103743 | s2cid = 247489555 }}) is an experimental monoclonal antibody drug for immune system conditions that neutralizes the human endogenous retrovirus envelope protein HERV-W.{{cite journal | vauthors = Mouliou DS, Dardiotis E | title = Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing? | journal = Multiple Sclerosis and Related Disorders | volume = 64 | pages = 103938 | date = August 2022 | pmid = 35717898 | pmc = 9169463 | doi = 10.1016/j.msard.2022.103938 }}{{cite journal | vauthors = Kornmann G, Curtin F | title = Temelimab, an IgG4 Anti-Human Endogenous Retrovirus Monoclonal Antibody: An Early Development Safety Review | journal = Drug Safety | volume = 43 | issue = 12 | pages = 1287–1296 | date = December 2020 | pmid = 32794123 | doi = 10.1007/s40264-020-00988-3 | s2cid = 221126453 }} It has been studied for multiple sclerosis up to phase 2b, where it was found to be safe and to reduce brain lesions. As of 2023, it is also being studied for cognitive impairment in long COVID.{{cite journal | vauthors = Bonilla H, Peluso MJ, Rodgers K, Aberg JA, Patterson TF, Tamburro R, Baizer L, Goldman JD, Rouphael N, Deitchman A, Fine J, Fontelo P, Kim AY, Shaw G, Stratford J, Ceger P, Costantine MM, Fisher L, O'Brien L, Maughan C, Quigley JG, Gabbay V, Mohandas S, Williams D, McComsey GA | display-authors = 6 | title = Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative | journal = Frontiers in Immunology | volume = 14 | pages = 1129459 | date = 2023-03-09 | pmid = 36969241 | pmc = 10034329 | doi = 10.3389/fimmu.2023.1129459 | doi-access = free }}